化疗期间使用促性腺激素释放激素激动剂保护早期乳腺癌绝经前患者卵巢功能与生育力的个体患者数据系统评价与Meta分析
该研究基于五项随机试验的873例早期乳腺癌绝经前患者个体数据,评估化疗期间同步使用GnRHa对卵巢功能和生育力的保护作用。结果显示GnRHa组卵巢早衰率显著低于对照组(14.1% vs 30.9%),治疗后妊娠率更高(10.3% vs 5.5%),且无病生存和总生存无显著差异。
要点
- 化疗期间同步GnRHa可降低早期乳腺癌绝经前患者卵巢早衰风险。
- GnRHa组治疗后妊娠率高于对照组,可能改善未来生育力。
- GnRHa对无病生存和总生存无显著不利影响。
核心结论
- 化疗期间临时卵巢抑制使用GnRHa可有效降低卵巢早衰风险并可能改善未来生育力,且不影响生存。
研究设计与样本
- 系统评价与Meta分析,纳入5项随机试验共873例早期乳腺癌绝经前患者,比较化疗联合GnRHa与单纯化疗。
临床怎么用
- 对于接受化疗的早期乳腺癌绝经前患者,可考虑同步使用GnRHa以降低化疗诱导的卵巢早衰风险并可能保留生育力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The role of temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal women remains controversial. This systematic review and meta-analysis using individual patient-level data was conducted to better assess the efficacy and safety of this strategy in patients with early breast cancer. Methods The trials in which premenopausal women with early breast cancer were randomly assigned to receive (neo)adjuvant chemotherapy alone or with concurrent GnRHa were eligible for inclusion. Primary end points were premature ovarian insufficiency (POI) rate and post-treatment pregnancy rate. Disease-free survival and overall survival were secondary end points. Because each study represents a cluster, statistical analyses were performed using a random effects model. Results A total of 873 patients from five trials were included. POI rate was 14.1% in the GnRHa group and 30.9% in the control group (adjusted odds ratio, 0.38; 95% CI, 0.26 to 0.57; P < .001). A total of 37 (10.3%) patients had at least one post-treatment pregnancy in the GnRHa group and 20 (5.5%) in the control group (incidence rate ratio, 1.83; 95% CI, 1.06 to 3.15; P = .030). No significant differences in disease-free survival (adjusted hazard ratio, 1.01; 95% CI, 0.72 to 1.42; P = .999) and overall survival (adjusted hazard ratio, 0.67; 95% CI, 0.42 to 1.06; P = .083) were observed between groups. Conclusion Our findings provide evidence for the efficacy and safety of temporary ovarian suppression with GnRHa during chemotherapy as an available option to reduce the likelihood of chemotherapy-induced POI and potentially improve future fertility in premenopausal patients with early breast cancer.
引用
- Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. J Clin Oncol. 2018. PMID: 29718793. doi:10.1200/JCO.2018.78.0858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。